local_hospital

Centre Hospitalier Universitaire De Dijon

Address
14 Rue Paul Gaffarel, 21000 Dijon, France

Oncology and Hematologic Malignancies

At Centre Hospitalier Universitaire De Dijon, a major share of research focuses on neoplasms and related blood cancers. Trials are studying diseases such as melanoma, lymphoma, breast cancer, lung cancer, biliary tract cancer, and bladder cancer, with the goal of improving treatment effectiveness, reducing recurrence, and refining post-surgical care.

  • Melanoma, including resected and advanced forms
  • Classical Hodgkin lymphoma and marginal zone lymphoma
  • Advanced biliary tract, colon, anal, and bladder cancers
  • Studies testing new immunotherapy and combination treatment strategies

These studies reflect a strong interest in better cancer control, especially for patients with advanced or high-risk disease.

Cardiovascular and Thrombotic Disease Research

The site also conducts important work in cardiovascular diseases and blood clotting disorders. Research includes acute coronary syndrome, atrial fibrillation, stroke, venous thromboembolism, and broader atherosclerotic risk, with trials aimed at preventing major events and improving long-term protection.

  • Stroke prevention after ischemic events or transient ischemic attack
  • Atrial fibrillation and clot prevention
  • Atherosclerotic cardiovascular risk and lipid-related disease
  • Balancing anticoagulation benefits with bleeding risk

Much of this research is designed to help clinicians choose safer and more effective ways to prevent heart attacks, strokes, and clot-related complications.

Respiratory and Critical Care Studies

Research in respiratory tract diseases and intensive care is another clear strength at this hospital. Trials cover COVID-19, community-acquired pneumonia, ventilator-associated pneumonia, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, and other progressive lung conditions, often focusing on treatment benefit in hospital settings.

  • COVID-19 treatment strategies in hospitalized patients
  • Severe bacterial pneumonia and ventilator-associated pneumonia
  • Progressive interstitial lung disease and pulmonary fibrosis
  • Therapies intended to improve recovery and survival

This area combines infection management with chronic lung disease care, reflecting a broad respiratory research portfolio.

Dermatology, Immune-Mediated, and Inflammatory Conditions

Clinical trials at the Dijon site also address skin and connective tissue diseases and immune system diseases. Key conditions include atopic dermatitis, psoriasis, hidradenitis suppurativa, prurigo nodularis, polymyalgia rheumatica, and Sjögren’s syndrome, with studies aimed at symptom control and better long-term disease management.

  • Chronic inflammatory skin diseases such as atopic dermatitis and psoriasis
  • Hidradenitis suppurativa and prurigo nodularis
  • Autoimmune and inflammatory disorders including polymyalgia rheumatica and Sjögren’s syndrome
  • Testing new therapies and treatment-sparing approaches

This research supports improved quality of life for patients living with persistent inflammatory conditions.

Eye Disease and Imaging Innovation

The department’s strong radiology and diagnostic imaging profile is reflected in trials on eye diseases and advanced imaging tools. Studies include glaucoma, macular edema, and imaging contrast evaluation, with the aim of preserving vision and improving diagnostic performance.

  • Glaucoma and visual field preservation
  • Macular edema linked to retinal vein occlusion
  • Evaluation of new MRI contrast agents
  • Research focused on better diagnosis and monitoring

These trials combine clinical eye care with imaging research, showing how the site links diagnosis and treatment innovation.

Digestive, Metabolic, and Surgical Oncology Research

Another active area involves digestive system diseases and nutritional and metabolic disorders. Trials cover ulcerative colitis, hypertriglyceridemia, colon carcinoma, and biliary tract carcinoma, often aiming to improve disease control, reduce relapse, or support better post-treatment outcomes.

  • Inflammatory bowel disease, especially ulcerative colitis
  • High triglycerides and related cardiovascular risk
  • Colon and biliary tract cancers after surgery or chemotherapy
  • Studies evaluating maintenance treatment and recurrence prevention

These projects highlight a mix of cancer, digestive, and metabolic research with practical implications for everyday care.

Neurology, Pregnancy, and Other Clinical Research Areas

Beyond its main specialties, the site contributes to trials in pathological conditions and broader clinical research, including intracerebral hemorrhage, preeclampsia, and pulmonary embolism. Some studies also involve healthy volunteers or imaging-related questions, supporting a wide-ranging research environment.

  • Brain bleeding and stroke-related outcomes
  • Pregnancy complications such as preeclampsia
  • Pulmonary embolism and anticoagulation decisions
  • Supportive research in imaging, prevention, and clinical surveillance

These trials show the breadth of clinical investigation at the Centre Hospitalier Universitaire De Dijon, extending well beyond one disease area.

Site Overview

assignment
478
connected trials
corporate_fare
143
sponsors
science
617
IMPs

Activity Indicator

Last 6 months

39
Trials started
-9% vs previous period.
43
Trials started 6–12 months ago
478
Total trials linked
Highly Active
trending_downDeclining-9%
4
8
9
9
6
3
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 4 of 27 therapeutic areas and 15 of 617 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 562 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
284
Sponsors (total)
143
Active sponsors
99

Sponsor Network

Top 99 by active trials.

lock +98 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +70 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 978 other sites in France

description
Trial volume
478
Outperforms 98% of sites
public
Therapeutic diversity
31areas
Outperforms 98% of sites
groups
Sponsor diversity
143sponsors
Outperforms 97% of sites

Therapeutic Area Benchmark — France

Select a therapeutic area to compare against other sites in France.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: France

Market Share

Country: France

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Centre Hospitalier Universitaire De Dijon

lock Showing 1 of 478 trials — the rest is available on a paid plan.

IMP list

lock Showing 1 of 617 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Rituximab37Unknown2014-03-242026-06-19

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.